1) Up to 3 lines of post-adjuvant or neoadjuvant therapy for TNBC/AYALA: AL-TNBC-01: A Phase 2, Multicenter, Open-label study of AL101 Monotherapy in Patients with Notch Activated Recurrent or Metastatic Triple Negative Breast Cancer
2) First line for locally advanced/ metastatic ER+ HER2 Neg/ BO41843: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GD9545 Combined with Palbociclib Compared with Letrozole Combined with Palbociclib in Patients with ER+, HER2 Neg Locally Advanced or Metastatic Breast Cancer
3) First and Second line of therapy (dependent upon monotherapy or combination therapy/Zeno 001: A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination with Palbociclib in Subjects with Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer.
4) First line advanced/metastatic ER+ HER2 Neg ZENO 003 (ON HOLD): A Phase 1B Study of ZN-c5 in Combination with Abemaciclib in Patients with Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
5) WO42633: A Phase 3, Randomized, Double Blind, Placebo Controlled Clinical Trail To Evaluate The Efficacy And Safety Of Adjuvant Atezolizumab OR Placebo And Trastuzumab Emtansine For HER2-Postive Breast Cancer At High Risk Of Recurrence Following Preoperative Therapy.
6) eMonoarch I3Y-MC-JPCW USO#20364: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in patients with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2 Targeted Therapy
Send UsA Message
I am currently undergoing treatment for breast cancer at Roper St. Francis Hospital and would like to acknowledge two physicians who truly embody your mission of “healing with compassion, faith and excellence”.
Please join Charleston Oncology and the American Association for Cancer Research (AACR) in support of National Survivor Month, celebrating those who have fought the disease and those currently in treatment.
June is National Cancer Survivor Month and throughout the month we are honoring our brave patients and sharing their inspirational stories.
May is Skin Cancer Awareness Month. Melanoma is a type of skin cancer that develops when melanocytes (the cells that give the skin its tan or brown color) start to grow out of control. Watch the video to learn more about melanoma from Charleston Oncology’s Dr. Charles S. Holladay.
March is Colorectal Cancer Awareness Month. This month, Charleston Oncology recognizes the importance of spreading awareness surrounding the disease.
Dr. Shelly Shand shares important tips for diagnosing breast cancer early and the latest advancements in breast cancer.